About Allchem Lifescience IPO
Allchem Lifescience IPO Details
Allchem Lifescience IPO is a 100% book-built issue, comprising a fresh issue of ₹190 crore and an offer for sale (OFS) of 71.55 lakh equity shares, with a face value of ₹10 per share. The company filed its DRHP with SEBI on March 13, 2025.
The price band and official dates of listing and subscription will be announced by the company later, but the shares are supposed to be listed on the BSE and the NSE platforms. The book-running lead manager of this issue is Emkay Global Financial Services Ltd. and the registrar to the issue is MUFG Intime India Private Ltd.
Allchem Lifescience IPO Date & Timeline
Allchem Lifescience Ltd. officially filed its Draft Red Herring Prospectus (DRHP) on March 13, 2025. However, the specific Allchem Lifescience IPO date and subscription timeline remain unannounced. Following regulatory approval, the company will finalize the price band and bidding dates. Once cleared, the schedule for anchor allotment, public bidding and the final listing on the exchange will be formally disclosed.
Allchem Lifescience IPO Timeline
| IPO Open Date | - |
| IPO Close Date | - |
| Tentative Allotment | - |
| Initiation of Refunds | - |
| Credit of Shares to Demat | - |
| Tentative Listing Date | - |
| Cut-off time for UPI mandate confirmation | - |
Allchem Lifescience IPO Details
| Detail | Description |
|---|---|
| IPO Date | - |
| Listing Date | - |
| Face Value | ₹ 10 per Equity Share |
| Issue Price Band | - |
| Lot Size | - |
| Sale Type | Book Built Offer |
| Total Issue Size | Up to ₹ 190 Cr + 7,155,000 Equity Shares |
| Reserved for Market Maker | - |
| Fresh Issue(Ex Market Maker) | Up to ₹ 190 Cr (aggregating up to ₹ 1,900 million) |
| Offer for Sale | Up to 71,55,000 Equity Shares |
| Net Offered to Public | - |
| Issue Type | Initial Public Offering (IPO) |
| Listing At | BSE and NSE |
| Share Holding Pre Issue | - |
| Share Holding Post Issue | - |
Allchem Lifescience IPO GMP (Grey Market Premium)
“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.
The Allchem Lifescience IPO GMP is currently trading at ₹[.], reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹[.], which is [.]% above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.
Company Background
Allchem Lifescience Ltd. was incorporated in 2017, in Vadodara, Gujarat, with a focus on manufacturing speciality chemicals and pharmaceutical intermediates. Over the years, the company has transitioned from a developing manufacturer to an established player in the chlorination chemistry space.
The company operates in a region known as a major hub for India's chemical and pharmaceutical industries, providing logistical and infrastructural advantages. Since its inception, Allchem has focused on building a portfolio catering to high-growth industries like healthcare and agriculture, marked by a shift towards more complex chemical processes and an expanding client base.
Operations & Product Range
Allchem Lifescience Ltd. is involved in the manufacturing of intricate chemical compounds, such as speciality chemicals and intermediates required in the development of Active Pharmaceutical Ingredients (APIs), as well as those required for the creation of agrochemicals. Its proficiency in chlorination technology has enabled it to develop different types of chlorinated products that are used in the production of pharmaceuticals, as well as pesticides and herbicides in agrochemicals.
Facilities & Capacity
The manufacturing plant of Allchem Lifescience Ltd. is a state-of-the-art one based in Village Lamdapura, Manjusar, Vadodara, Gujarat. This plant is fitted with advanced reactors that can carry out high-pressure chemical reactions. The company is strategically located, the plant is near the sources of raw materials and big ports, which helps with easy transportation both within the country and abroad.
Brands & Market Presence
Allchem Lifescience Ltd. is mainly involved in the business of manufacturing goods for industry and institutions, where its presence in the market is based on its technical image and quality of products. The company has made a place for itself as a dependable vendor in the industrial corridor of Gujarat. Its exposure to exports protects it from any volatility in its home market and confirms that it adheres to global manufacturing norms.
Revenue Streams & Business Model
The primary revenue stream of Allchem Lifescience Ltd. is the sale of specialty chemicals and intermediates. The business model is centred on "Chemistry with Excellence," focusing on mastering specific chemical processes to offer high-value products to industrial buyers. In FY24, total revenue was ₹138.06 crore, with significant contributions from the pharmaceutical intermediate segment, followed by specialty chemicals and agrochemicals, as well as the export income of ₹54.53 crore, further showcasing the company's global competitiveness.
Management & Shareholding
The promoters of Allchem Lifescience Ltd. are Bipin Patel, Kantilal Ramanlal Patel, Aditi Patel and Manisha Bipin Patel. Before the IPO, the promoters collectively held the 99.98% of the pre-IPO shareholding, with the 0.02% held by the promoter group. But after the IPO, the promoter shareholding will be diluted through the fresh issue and OFS.
Board & Key Management
The leadership of Allchem Lifescience Ltd. is led by a team of experts with many years of experience. Bipin Patel serves as the Chairman & Managing Director and gives strategic direction to the firm and the daily operations, along with Whole-Time Directors Kantilal Ramanlal Patel and Aditi Patel. To ensure good governance, the board includes Independent Directors Lavina Bharatkumar Chuggani, Hemang Mehta and Rajnikanth Chimanlal Diwan for honest oversight. Together, this team uses its knowledge to help the company grow and stay successful.
Allchem Lifescience IPO Financial Information
Latest Revenue
78.53
₹ Crore
Profit After Tax
10.89
₹ Crore
Net Worth
90.74
₹ Crore
Total Borrowing
106.9
₹ Crore
| Period Ended | Assets | Total Income | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 2024 | 246.3 | 78.53 | 10.89 | 90.74 | 86.49 | 106.9 | |||
| 31 Mar 2024 | 224.65 | 138.07 | 23.41 | 79.89 | 75.64 | 104.97 | |||
| 31 Mar 2023 | 186.68 | 106.03 | 17.99 | 56.49 | 52.24 | 97.17 | |||
| 31 Mar 2022 | 124.02 | 109.42 | 14.14 | 38.58 | 35.08 | 49.53 | |||
| Amount in ₹ Crore | |||||||||
Allchem Lifescience Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 34.33% |
| ROCE | 22.87% |
| Debt/Equity | 1.31x |
| RoNW | 34.33% |
| PAT Margin | 17.03% |
| EBITDA Margin | - |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 3.06 | - |
| P/E (x) | - | - |
Allchem Lifescience IPO Objectives
The company intended to utilise the Allchem Lifescience IPO proceeds for strategic purposes:
- • Funding the working capital requirements
- • General corporate purposes
Allchem Lifescience IPO Review
Allchem Lifescience Ltd. is engaged in the fast-growing speciality chemicals industry, owing to its “China Plus One” approach and the increasing importance of India as a manufacturer. The company’s emphasis on pharmaceutical and agrochemical intermediates places it in defensive markets that have steady demand in any economic environment.
Financially, the company has shown growing and healthy financial statements, with a total revenue of ₹138.06 crore and a PAT of ₹23.40 crore in FY24. The company operates with respectable margins that reflect a significant operational scale-up.
However, investors should consider risks, including dependency on a single manufacturing facility and raw material price volatility. Overall, the IPO Review suggests that future performance will depend on managing capacity expansion and maintaining quality standards in a competitive market.
Conclusion
The Allchem Lifescience IPO represents an opportunity for investors to participate in the growth of a specialised chemical manufacturer focused on high-demand intermediates. The firm uses a concentrated strategy in developing expertise and building a stable financial management. The Indian niche chemical industry is expected to grow further in the future and R&D and its presence in Gujarat will continue to form a cornerstone of its strategy.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Expertise in the field of chlorination chemistry makes it possible for the company to manufacture complex intermediates that have high barriers to entry.
Location near the industrial centre of Vadodara provides an advantage in accessing raw materials and skilled labour.
The company has been growing steadily in terms of revenue and profit generation.
Relationships with leading pharmaceutical and agrochemical companies ensure revenue visibility.
| Sr.no | Description | Date | File |
|---|---|---|---|
| 1 | SEBI/Exchange approval received | 21/08/2025 | - |
| 2 | Filed with SEBI/Exchange | 18/03/2025 | View DRHP |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | — | ~₹14,000 - ₹15,000 |
| Individual investors (Retail) (Max) | 13-14 | — | Up to ₹200,000 |
| S-HNI (Min) | 14-15 | — | Over ₹200,000 |
| S-HNI (Max) | 66-70 | — | Up to ₹10,00,000 |
| B-HNI (Min) | 71+ | — | Over ₹10,00,000 |